The first implants of Cre8™ were performed in New Zealand following the successfull launch of Cre8™ in Australia.
The procedures took place in Christchurch, NZ and the reception of the stent was excellent.
Cre8™ has received great feedback on its deliverability, crossability, visibility, conformability and overall stent performance in comparison to the competition. In addition, Cre8™ is a stent that can provide additional benefit to diabetic patients due to its unique technologies. The Amphilimus™ formulation, which is a combination of Sirolimus and a Fatty acid, is especially effective on diabetic patients optimizing effectiveness, and Cre8™ being a polymer free stent together with our Bio Inducer Surface insures a very high safety for the patient.
